GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Femtobiomed Inc (XKRX:327610) » Definitions » Beneish M-Score

Femtobiomed (XKRX:327610) Beneish M-Score : 26.47 (As of Jun. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Femtobiomed Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 26.47 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Femtobiomed's Beneish M-Score or its related term are showing as below:

XKRX:327610' s Beneish M-Score Range Over the Past 10 Years
Min: -11.22   Med: -2.47   Max: 26.47
Current: 26.47

During the past 6 years, the highest Beneish M-Score of Femtobiomed was 26.47. The lowest was -11.22. And the median was -2.47.


Femtobiomed Beneish M-Score Historical Data

The historical data trend for Femtobiomed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femtobiomed Beneish M-Score Chart

Femtobiomed Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - -3.04 -11.22 -1.89 26.47

Femtobiomed Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score Get a 7-Day Free Trial - -3.04 -11.22 -1.89 26.47

Competitive Comparison of Femtobiomed's Beneish M-Score

For the Biotechnology subindustry, Femtobiomed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Femtobiomed's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Femtobiomed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Femtobiomed's Beneish M-Score falls into.



Femtobiomed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Femtobiomed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 31.8985+0.528 * 0.5499+0.404 * 0.8153+0.892 * 1.8212+0.115 * 0.8304
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4655+4.679 * 0.030657-0.327 * 1.3344
=26.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was ₩367.6 Mil.
Revenue was ₩334.0 Mil.
Gross Profit was ₩208.5 Mil.
Total Current Assets was ₩2,094.0 Mil.
Total Assets was ₩3,287.2 Mil.
Property, Plant and Equipment(Net PPE) was ₩909.2 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩642.7 Mil.
Selling, General, & Admin. Expense(SGA) was ₩626.8 Mil.
Total Current Liabilities was ₩11,987.7 Mil.
Long-Term Debt & Capital Lease Obligation was ₩121.6 Mil.
Net Income was ₩-2,248.5 Mil.
Gross Profit was ₩0.0 Mil.
Cash Flow from Operations was ₩-2,349.3 Mil.
Total Receivables was ₩6.3 Mil.
Revenue was ₩183.4 Mil.
Gross Profit was ₩63.0 Mil.
Total Current Assets was ₩2,352.4 Mil.
Total Assets was ₩4,071.4 Mil.
Property, Plant and Equipment(Net PPE) was ₩1,287.5 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩674.9 Mil.
Selling, General, & Admin. Expense(SGA) was ₩739.4 Mil.
Total Current Liabilities was ₩11,105.1 Mil.
Long-Term Debt & Capital Lease Obligation was ₩134.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(367.612 / 333.954) / (6.328 / 183.372)
=1.100786 / 0.034509
=31.8985

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(62.962 / 183.372) / (208.505 / 333.954)
=0.343357 / 0.624352
=0.5499

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2093.986 + 909.168) / 3287.193) / (1 - (2352.354 + 1287.536) / 4071.404)
=0.086408 / 0.105987
=0.8153

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=333.954 / 183.372
=1.8212

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(674.896 / (674.896 + 1287.536)) / (642.746 / (642.746 + 909.168))
=0.343908 / 0.414163
=0.8304

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(626.791 / 333.954) / (739.405 / 183.372)
=1.876878 / 4.032268
=0.4655

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((121.626 + 11987.741) / 3287.193) / ((134.494 + 11105.096) / 4071.404)
=3.683802 / 2.760618
=1.3344

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2248.524 - 0 - -2349.298) / 3287.193
=0.030657

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Femtobiomed has a M-score of 26.47 signals that the company is likely to be a manipulator.


Femtobiomed Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Femtobiomed's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Femtobiomed (XKRX:327610) Business Description

Traded in Other Exchanges
N/A
Address
17 Pangyo-ro 228 (ibaegisippal) beo, Sampyeong-dong, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13487
Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.

Femtobiomed (XKRX:327610) Headlines

No Headlines